Chronic Kidney Diseaseā€“Mineral and Bone Disorders (CKD-
MBD) Market
Chronic Kidney Diseaseā€“Mineral and Bone Disorders
(CKD-MBD) Market Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Chronic Kidney Diseaseā€“Mineral and Bone Disorders (CKD-MBD) Market Size and Growth
The Chronic Kidney Diseaseā€“Mineral and Bone Disorders (CKD-MBD) market is expanding due to increasing CKD prevalence and growing awareness of associated complications. The global CKD-MBD market size is projected to reach approximately $2 billion by 2025, driven by advancements in treatment options and rising affordability of therapies.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
ā—¨ Akebia
ā—¨ Astellas
ā—¨ Takeda
ā—¨ Vifor
ā—¨ Abbvie
ā—¨ Fresenius
ā—¨ Abbott
ā—¨ Novadiol
ā—¨ Japan Tobacco Company
ā—¨ Daiichi-Sankyo
ā—¨ Shield
ā—¨ Spectrum
ā—¨ OPKO
ā—¨ Ardelyx
ā—¨ Sanofi Genzyme
ā—¨ Amgen
The CKD-MBD market features key players like Akebia, Astellas, and Amgen, focusing on innovative therapies and market expansion. Companies invest in R&D and collaboration to enhance treatment options. Sales figures: Amgen reported $23 billion (2022), AbbVie $58 billion (2021), and Fresenius $38 billion (2021), demonstrating significant market impact. Request Sample Report
Market Segmentation
By Application
ā—¨ Hospital Pharmacies
ā—¨ Retail Pharmacies
ā—¨ Online Pharmacies
ā—¨ Drug Stores
By Product
ā—¨ Control Hyperphosphatemia
ā—¨ Maintain Blood Calcium Levels
ā—¨ Control PTH Level ā—¨ Correct Acidosis ā—¨ Other
ā—¨ Other Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
